Could a single iron infusion ease heart failure in seniors?

NCT ID NCT07686692

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether a single intravenous dose of iron (ferric derisomaltose) can improve symptoms, reduce hospitalizations, and boost quality of life in adults aged 65 and older who have heart failure with preserved ejection fraction and iron deficiency. Participants receive either the iron infusion or a placebo, and researchers track outcomes like survival, hospital stays, and physical function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ferric derisomaltose (intravenous iron)
What this could lead to
If it works, this could offer a simple infusion to improve daily function and reduce hospital stays for older adults with heart failure and low iron.
What could go wrong
This is a single-dose study in a specific older population; results may not apply to all heart failure patients. Iron overload or allergic reactions are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Duke University Health System

    Durham, North Carolina, 27705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.